TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 2.10nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 2.30nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 2.5nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 2.70nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 3.30nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 3.30nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 3.40nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 5.10nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 5.5nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 6.40nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 9.10nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 9.30nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 10.9nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 12nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 12nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 12.8nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 14nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 14nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 14nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 14nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 27nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 27.7nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 34nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 34nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 35nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
TargetALK tyrosine kinase receptor(Homo sapiens (Human))
Guangzhou Maxinovel Pharmaceuticals
US Patent
Guangzhou Maxinovel Pharmaceuticals
US Patent
Affinity DataIC50: 36nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair